Cardiff Oncology (CRDF) CFO discloses initial holding of 500 common shares

Q: Is the Cardiff Oncology (CRDF) Form 3 a buy or sell transaction?

The Cardiff Oncology Form 3 is not a buy or sell report . It is an initial statement of beneficial ownership, showing CFO Joshua B. Muntner holds 500 Common Stock shares directly, without disclosing any new purchase or sale activity.

Q: What type of security is reported in the Cardiff Oncology (CRDF) Form 3?

The Form 3 reports beneficial ownership of Cardiff Oncology Common Stock . CFO Joshua B. Muntner lists 500 shares held directly, with no derivative securities or option positions included in the disclosed holdings in this filing.

Q: Does the Cardiff Oncology (CRDF) Form 3 indicate derivative holdings for the CFO?

The Form 3 for Cardiff Oncology’s CFO shows no derivative securities in the derivative section. It only lists 500 shares of Common Stock held directly, with no options, warrants, or other derivative positions disclosed in this filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cardiff Oncology, Inc. Chief Financial Officer Joshua B. Muntner filed an initial statement of beneficial ownership, reporting direct holdings of 500 shares of Common Stock. This Form 3 reflects his existing ownership position and does not show any reported purchases, sales, or option exercises.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Muntner Joshua B

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 500 shares (Direct)

Footnotes (1)

Key Figures

Common Stock held: 500 shares Insider filing type: Form 3

2 metrics

Common Stock held 500 shares Direct beneficial ownership reported on Form 3

Insider filing type Form 3 Initial statement of beneficial ownership by CFO

Key Terms

Form 3, beneficial ownership, Common Stock

3 terms

Form 3 regulatory

"Chief Financial Officer Joshua B. Muntner filed an initial statement of beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"filed an initial statement of beneficial ownership, reporting direct holdings"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Common Stock financial

"reporting direct holdings of 500 shares of Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Understanding Insider Trading Forms →

04/16/2026 - 08:08 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Muntner Joshua B

(Last)

(First)

(Middle)

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/06/2026

3. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	500	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

	/s/ Joshua Muntner	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Form 3 filing by Cardiff Oncology (CRDF) CFO show?

The Form 3 shows Chief Financial Officer Joshua B. Muntner directly holds 500 shares of Cardiff Oncology Common Stock. This is an initial beneficial ownership report and does not indicate any recent purchases or sales of shares.

How many Cardiff Oncology (CRDF) shares does CFO Joshua Muntner own?

CFO Joshua B. Muntner reports direct beneficial ownership of 500 shares of Cardiff Oncology Common Stock. This figure reflects his position disclosed in the Form 3 and is not tied to a specific buy or sell transaction.

Is the Cardiff Oncology (CRDF) Form 3 a buy or sell transaction?

The Cardiff Oncology Form 3 is not a buy or sell report. It is an initial statement of beneficial ownership, showing CFO Joshua B. Muntner holds 500 Common Stock shares directly, without disclosing any new purchase or sale activity.

What type of security is reported in the Cardiff Oncology (CRDF) Form 3?

The Form 3 reports beneficial ownership of Cardiff Oncology Common Stock. CFO Joshua B. Muntner lists 500 shares held directly, with no derivative securities or option positions included in the disclosed holdings in this filing.

Does the Cardiff Oncology (CRDF) Form 3 indicate derivative holdings for the CFO?

The Form 3 for Cardiff Oncology’s CFO shows no derivative securities in the derivative section. It only lists 500 shares of Common Stock held directly, with no options, warrants, or other derivative positions disclosed in this filing.